SERES THERAPEUTICS INC's ticker is MCRB and the CUSIP is 81750R102. A total of 125 filers reported holding SERES THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $115,539 | -48.5% | 48,546 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $224,268 | +16.3% | 46,820 | +37.7% | 0.00% | 0.0% |
| Q1 2023 | $192,814 | +3.3% | 34,006 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $186,648 | -13.2% | 33,330 | -0.4% | 0.00% | -50.0% |
| Q3 2022 | $215,000 | +90.3% | 33,451 | +1.4% | 0.00% | +100.0% |
| Q2 2022 | $113,000 | -54.1% | 32,978 | -4.6% | 0.00% | 0.0% |
| Q1 2022 | $246,000 | -20.1% | 34,554 | -6.6% | 0.00% | -50.0% |
| Q4 2021 | $308,000 | +16.2% | 36,988 | -2.9% | 0.00% | +100.0% |
| Q3 2021 | $265,000 | -71.5% | 38,094 | -2.3% | 0.00% | -66.7% |
| Q2 2021 | $930,000 | +40.3% | 38,999 | +21.1% | 0.00% | +50.0% |
| Q1 2021 | $663,000 | -15.8% | 32,191 | +0.3% | 0.00% | -33.3% |
| Q4 2020 | $787,000 | -12.5% | 32,105 | +1.1% | 0.00% | -25.0% |
| Q3 2020 | $899,000 | +602.3% | 31,748 | +18.1% | 0.00% | +300.0% |
| Q2 2020 | $128,000 | +66.2% | 26,874 | +24.4% | 0.00% | – |
| Q1 2020 | $77,000 | -2.5% | 21,595 | -5.5% | 0.00% | – |
| Q4 2019 | $79,000 | -14.1% | 22,843 | -0.8% | 0.00% | – |
| Q3 2019 | $92,000 | +109.1% | 23,035 | +69.0% | 0.00% | – |
| Q2 2019 | $44,000 | -51.1% | 13,634 | +3.8% | 0.00% | – |
| Q1 2019 | $90,000 | +47.5% | 13,131 | -3.1% | 0.00% | – |
| Q4 2018 | $61,000 | -41.3% | 13,555 | -0.8% | 0.00% | – |
| Q3 2018 | $104,000 | -9.6% | 13,660 | +1.8% | 0.00% | – |
| Q2 2018 | $115,000 | +19.8% | 13,414 | +2.6% | 0.00% | – |
| Q1 2018 | $96,000 | -31.4% | 13,073 | -5.1% | 0.00% | – |
| Q4 2017 | $140,000 | -36.4% | 13,777 | +0.5% | 0.00% | -100.0% |
| Q3 2017 | $220,000 | +53.8% | 13,712 | +8.1% | 0.00% | 0.0% |
| Q2 2017 | $143,000 | +15.3% | 12,687 | +15.6% | 0.00% | – |
| Q1 2017 | $124,000 | +22.8% | 10,977 | +7.1% | 0.00% | – |
| Q4 2016 | $101,000 | -99.9% | 10,250 | -0.3% | 0.00% | -100.0% |
| Q3 2016 | $126,304,000 | -57.6% | 10,277 | +0.1% | 0.00% | 0.0% |
| Q2 2016 | $298,111,000 | +125.8% | 10,262 | +106.4% | 0.00% | 0.0% |
| Q1 2016 | $132,000,000 | – | 4,972 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Pioneering Inc. | 23,117,045 | $110,730,646 | 4.94% |
| Lion Point Capital, LP | 691,803 | $3,313,736 | 1.50% |
| Eversept Partners, LP | 3,076,756 | $14,737,661 | 1.23% |
| Soleus Capital Management, L.P. | 2,045,983 | $9,800,259 | 1.09% |
| Knott David M Jr | 470,000 | $2,251 | 0.90% |
| GREAT POINT PARTNERS LLC | 938,067 | $4,493,341 | 0.88% |
| Simplify Asset Management Inc. | 550,626 | $2,637,499 | 0.35% |
| Delphia (USA) Inc. | 33,913 | $162,443 | 0.26% |
| Alpha DNA Investment Management LLC | 138,536 | $663,587 | 0.22% |
| Avoro Capital Advisors LLC | 2,500,000 | $11,975,000 | 0.16% |